NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research ChannelBioSpace Collaborative Employers
 Post Job | Search Resumes | Login

 Top Breaking News
 Friday, July 30, 2010

FDA Warns About Pneumonia Caused By Cubist Pharmaceuticals, Inc. (CBST)'s Antibiotic Cubicin    More...

Orexigen Therapeutics, Inc. (OREX) Obesity Pill Shows Promise in Phase III Study; Stock Rises 9.47% at 1:20PM EDT    More...

Geron Corporation (GERN) Gets Human Trial Nod For Spinal Cord Therapy; FDA Lifts Clinical Hold On Human Trial Application    More...

Allergan Inc. (AGN) Eye Drug Wins EU OK For Fluid Buildup    More...

FDA Advisory Committee Recommends Approval of AstraZeneca PLC (AZN)'s Brilinta (Ticagrelor) for Acute Coronary Syndromes; AstraZeneca Lifts Forecast Due to Ruling    More...

Shionogi, Inc. Announces FDA Approval of CUVPOSA for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions    More...

Abbott Laboratories (ABT)'s SIMCOR(R) (Niacin Extended-Release/Simvastatin ) Receives FDA Approval for New Dosage Strengths    More...

Pfizer Inc. (PFE)'s Viagra Weighed by U.S. FDA for Children With Rare Lung Disorder    More...

More News



 Market Summary

 Yesterday's Most Popular News 
Super-Sizing A Cancer Drug Minimizes Side Effects, Harvard University And Massachusetts Institute of Technology (MIT) Study    More...

FDA Advisory Committee Recommends Approval of AstraZeneca PLC (AZN)'s Brilinta (Ticagrelor) for Acute Coronary Syndromes; AstraZeneca Lifts Forecast Due to Ruling    More...

Breaching the Blood-Brain Barrier To Create Powerful New Tools for Fighting Cancer, Rensselaer Polytechnic Institute Study    More...

Patients 'Could Grow New Joints', Columbia University, University of Missouri And Clemson University Study    More...

Shionogi, Inc. Announces FDA Approval of CUVPOSA for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions    More...

Abbott Laboratories (ABT)'s SIMCOR(R) (Niacin Extended-Release/Simvastatin ) Receives FDA Approval for New Dosage Strengths    More...

BioNovo, Inc. (BNVI) to Advance Menerba to Phase 3 Clinical Testing in Europe    More...

Pfizer Inc. (PFE)'s Viagra Weighed by U.S. FDA for Children With Rare Lung Disorder    More...

Allos Therapeutics, Inc. (ALTH)'s Cancer Drug, Folotyn Extends Lung Cancer Survival    More...

Tris Pharma, Inc. Announces Approval of First-Time Generic of Methylphenidate Hydrochloride Oral Solution With Six Months Exclusivity    More...


 
Job Search     

Advanced Search

 Featured Stories
 
Risk of MI May Go Up With Calcium Supplements, University of Auckland Study    More...
Dense Bones Linked To Raised Risk For Prostate Cancer, National Institute on Aging and Johns Hopkins University School of Medicine Study    More...
Cell-of-Origin for Human Prostate Cancer Identified for First Time, University of California, Los Angeles (UCLA) Study    More...
Protein Complex Helps Cancer Cells Fight Platinum-Based Drugs By Fixing DNA Cross-Links, University of Texas MD Anderson Cancer Center and Zhejiang University Pharmaceutical Study    More...
Knee, Hip Replacements May Aid Weight Loss: Mount Sinai School of Medicine Study    More...
Fluorescent Biosensor to Aid in Drug Development, Carnegie Mellon University Study    More...
Scientists Post Lower Speed Limit For Cell-Signaling Protein Assembly, Michigan State University Study    More...
Super-Sizing A Cancer Drug Minimizes Side Effects, Harvard University And Massachusetts Institute of Technology (MIT) Study    More...
More Featured Stories


 Featured Employer
Founded on the principle that strong science would lead to important new medicines, Regeneron has become an integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. Regeneron currently markets ARCALYST® (rilonacept) Injection for Subcutaneous Use for the treatment of a rare, inherited, inflammatory condition. Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, central retinal vein occlusion, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer.

Show me jobs for this employer

 Careers
 
You're the Perfect Fit, So Why Did the Hiring Manager Say, "No"?    More...

Addressing Salary Requirements in a Cover Letter    More...

Smart Tips for Getting a Job: A Better Approach    More...

Five Tips for Acing a Phone Interview    More...

Tips to Make Your Job Interview a Success    More...

Don't Be a Perfectionist in Your Job Search    More...

Poll: How Much Is Beauty Worth at Work?    More...

Smart Employers and Smart Job Applicants Seek the Same Thing    More...

Seven Ways Not to Use Your Connections to Get a Job    More...

Top Tips for Job Hunters: Successfully Field Interview Questions to Get the Job    More...

More Career Tips